

# Theodore W K Ng

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8382120/publications.pdf>

Version: 2024-02-01

22  
papers

991  
citations

567281  
15  
h-index

677142  
22  
g-index

22  
all docs

22  
docs citations

22  
times ranked

1817  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Dietary Fatty Acids on Human Lipoprotein Metabolism: A Comprehensive Update. <i>Nutrients</i> , 2015, 7, 4416-4425.	4.1	101
2	Association of Plasma Ceramides and Sphingomyelin With VLDL apoB-100 Fractional Catabolic Rate Before and After Rosuvastatin Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2497-2501.	3.6	24
3	Dose-Dependent Effects of Rosuvastatin on the Plasma Sphingolipidome and Phospholipidome in the Metabolic Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2335-E2340.	3.6	59
4	Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 519-526.	4.4	11
5	Metabolomics and ischaemic heart disease. <i>Clinical Science</i> , 2013, 124, 289-306.	4.3	43
6	Omega-3 fatty acid ethyl ester supplementation decreases very-low-density lipoprotein triacylglycerol secretion in obese men. <i>Clinical Science</i> , 2013, 125, 45-51.	4.3	17
7	Dietary fatty acids and lipoprotein metabolism. <i>Current Opinion in Lipidology</i> , 2013, 24, 192-197.	2.7	43
8	Apolipoprotein A-II: Evaluating its significance in dyslipidaemia, insulin resistance, and atherosclerosis. <i>Annals of Medicine</i> , 2012, 44, 313-324.	3.8	35
9	Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome. <i>Journal of Lipid Research</i> , 2012, 53, 2443-2449.	4.2	15
10	Investigating the pathogenesis and risk of Type 2 diabetes: clinical applications of metabolomics. <i>Clinical Lipidology</i> , 2012, 7, 641-659.	0.4	11
11	Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease. <i>Journal of Lipid Research</i> , 2011, 52, 794-800.	4.2	53
12	Genetic determinants of apolipoprotein B-100 kinetics. <i>Current Opinion in Lipidology</i> , 2010, 21, 141-147.	2.7	5
13	Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndrome. <i>Clinical Science</i> , 2010, 118, 79-85.	4.3	15
14	Plasma markers of cholesterol homeostasis in metabolic syndrome subjects with or without type-2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2009, 85, 310-316.	2.8	28
15	Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome. <i>European Journal of Clinical Investigation</i> , 2008, 38, 743-751.	3.4	56
16	Effect of Weight Loss on LDL and HDL Kinetics in the Metabolic Syndrome. <i>Diabetes Care</i> , 2007, 30, 2945-2950.	8.6	90
17	Measurement of liver fat by magnetic resonance imaging: relationships with body fat distribution, insulin sensitivity and plasma lipids in healthy men. <i>Diabetes, Obesity and Metabolism</i> , 2006, 8, 698-702.	4.4	50
18	Association of adiponectin and resistin with adipose tissue compartments, insulin resistance and dyslipidaemia. <i>Diabetes, Obesity and Metabolism</i> , 2005, 7, 406-413.	4.4	125

#	ARTICLE	IF	CITATIONS
19	Does pravastatin increase chylomicron remnant catabolism in postmenopausal women with type 2 diabetes mellitus?. Clinical Endocrinology, 2005, 63, 650-656.	2.4	5
20	Apolipoprotein B-100 kinetics and static plasma indices of triglyceride-rich lipoprotein metabolism in overweight men. Clinical Biochemistry, 2005, 38, 806-812.	1.9	7
21	Adipocytokines and VLDL Metabolism: Independent Regulatory Effects of Adiponectin, Insulin Resistance, and Fat Compartments on VLDL Apolipoprotein B-100 Kinetics?. Diabetes, 2005, 54, 795-802.	0.6	105
22	Adiponectin and other Adipocytokines as Predictors of Markers of Triglyceride-Rich Lipoprotein Metabolism. Clinical Chemistry, 2005, 51, 578-585.	3.2	93